EGFR and non-small cell lung carcinoma: This report provides the first reported evidence for the use of brigatinib monotherapy in patients with NSCLC harboring <i>EGFR</i> del19/T790M/cis-C797S mutations after progression to previous <i>EGFR</i>-TKIs.